Sutton Wealth Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Sutton Wealth Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$1.82K	Hold	15	–	–	﹤0.01%	736
2023 Q2	$1.72K	Hold	15	–	–	﹤0.01%	719
2023 Q1	$2.07K	Hold	15	–	–	﹤0.01%	639
2022 Q4	$1.94K	Hold	15	–	–	﹤0.01%	1209
2022 Q3	$1.66K	Hold	15	–	–	﹤0.01%	1208
2022 Q2	$1.12K	Hold	15	–	–	﹤0.01%	1253
2022 Q1	$1.17K	Hold	15	–	–	﹤0.01%	1300
2021 Q4	$1.35K	Sell	15 -3	-17%	-$256	﹤0.01%	1259
2021 Q3	$1.67K	Buy	18 +2	+13%	+$154	﹤0.01%	1192
2021 Q2	$1.24K	Buy	+16	New	+$1.21K	﹤0.01%	1211
2020 Q1	–	Sell	-1	Closed	-$129	–	1254
2019 Q4	$129	Sell	1 -35	-97%	-$3.53K	﹤0.01%	1159
2019 Q3	$2.71K	Hold	36	–	–	﹤0.01%	1025
2019 Q2	$5.47K	Hold	36	–	–	﹤0.01%	913
2019 Q1	$4.29K	Sell	36 -95	-73%	-$12.2K	﹤0.01%	964
2018 Q4	$14.3K	Hold	131	–	–	0.01%	638
2018 Q3	$21.2K	Hold	131	–	–	0.01%	566
2018 Q2	$17.3K	Buy	+131	New	+$12.4K	0.01%	648

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Sutton Wealth Advisors's SRPT Position: Q3 2023 in Review

Sutton Wealth Advisors held its Sarepta Therapeutics (SRPT) position steady in Q3 2023 at 15 shares worth $1.82K. The position accounts for ﹤0.01% of the portfolio, ranked #736.

Sutton Wealth Advisors first reported a position in SRPT in Q2 2018 and has held it in 17 quarters since. The position peaked at $21.2K in Q3 2018. 395 funds tracked by Wall St. Rank hold SRPT as of Q3 2023.

Sutton Wealth Advisors held 15 shares of Sarepta Therapeutics worth $1.82K as of Q3 2023.
Sutton Wealth Advisors left its Sarepta Therapeutics share count unchanged in Q3 2023.
Sarepta Therapeutics made up ﹤0.01% of Sutton Wealth Advisors's portfolio in Q3 2023, its #736 holding.
Sutton Wealth Advisors first reported a position in Sarepta Therapeutics in Q2 2018 and has held it in 17 quarters since.
Sutton Wealth Advisors's Sarepta Therapeutics position peaked at $21.2K in Q3 2018.
395 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2023.

Based on Sutton Wealth Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.